Sandra Beaver Sells 6,494 Shares of Evolus, Inc. (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 6,494 shares of the firm’s stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total transaction of $65,069.88. Following the completion of the sale, the chief financial officer now owns 167,089 shares in the company, valued at approximately $1,674,231.78. The trade was a 3.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Sandra Beaver also recently made the following trade(s):

• On Tuesday, March 18th, Sandra Beaver sold 8,996 shares of Evolus stock. The stock was sold at an average price of $13.26, for a total value of $119,286.96.

Evolus Stock Up 0.1%

Shares of NASDAQ EOLS opened at $10.00 on Friday. The stock has a market cap of $644.76 million, a PE ratio of -10.99 and a beta of 1.11. The business has a fifty day moving average of $11.38 and a two-hundred day moving average of $12.41. Evolus, Inc. has a 52-week low of $8.67 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47.

Analyst Upgrades and Downgrades

Several brokerages recently commented on EOLS. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, April 10th. BTIG Research began coverage on Evolus in a research report on Thursday, April 17th. They issued a “buy” rating and a $21.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. Finally, Barclays raised their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $23.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in EOLS. AlphaQuest LLC bought a new position in shares of Evolus during the first quarter valued at $39,000. State of Wyoming lifted its holdings in shares of Evolus by 988.1% during the first quarter. State of Wyoming now owns 3,754 shares of the company’s stock valued at $45,000 after acquiring an additional 3,409 shares during the period. KBC Group NV bought a new position in shares of Evolus during the fourth quarter valued at $49,000. IFP Advisors Inc lifted its holdings in shares of Evolus by 17,440.7% during the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Evolus during the fourth quarter valued at $106,000. 90.69% of the stock is owned by institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.